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Case presentation
A 70-year-old white male was admitted to the Veterans Administra-
tion Medical Center for evaluation of chronic renal failure. The diagno-
sis of polycystic kidney disease (with concomitant cystic disease of the
pancreas and liver) had been established 9 years prior to admission.
Over the past several years, renal function had been stable, with serum
creatinine and BUN levels remaining at 4.5 mg/dl and 50 mg/dl,
respectively. Other significant problems included seronegative psoriatic
arthritis, paroxysmal atrial tachycardia, and persistent normochromic,
normocytic anemia. On a routine visit to renal clinic, the BUN was 95
mg/dl and the serum creatinine, 9.1 mg/dl. He was admitted to the
hospital to determine the cause of the deterioration in renal function.
On admission, the blood pressure was 150/50 mm Hg. Physical
examination was remarkable for diffuse psoriasis, ulnar deviation of
both hands, and swan-neck deformity of the fingers. The remainder of
the physical examination was normal except for bilateral pedal edema.
Laboratory findings revealed: hematocrit, 24.2; white blood cell count,
7800/mm3; platelets, 223,000/mm3; prothrombin time, 12.9 seconds
(11.5 seconds, control); partial thromboplastin time, 34.5 seconds (35.4
seconds, control); serum sodium, 133 mEq/liter; potassium, 6.8 mEq/
liter; chloride, 95 mEq/liter; bicarbonate, 21 mM/liter; calcium, 9.1 mgI
dl; and phosphorus, 5.8 mg/dl. Urinalysis on admission revealed 3+
protein and no cellular elements, but subsequent urinalyses revealed
intermittent episodes of microscopic or gross heniaturia.
Shortly after admission the patient passed blood clots in his urine.
Retrograde cystoscopy revealed obstruction of the right ureter second-
ary to a blood clot, thought to be due to bleeding arising from a cyst. A
right ureteral catheter was inserted to relieve the obstruction. Renal
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function did not improve, however, and the decision was made to offer
the patient permanent hemodialysis.
The hemostasis service was consulted prior to fistula placement. The
Ivy bleeding time (Simplate II, General Diagnostic Division, Warner-
Lambert, Morris Plains, NJ) was 24 minutes (normal, less than 7
minutes). The platelet count, prothrombin time, and activated partial
thromboplastin time tests were normal. The patient's platelets aggregat-
ed normally in response to ADP, epinephrine, collagen, and arachidonic
acid. On the day the arteriovenous fistula was surgically created, the
patient was given 10 bags of cryoprecipitate prepared by the Boston
Chapter of the American Red Cross. Four hours later his bleeding time
shortened to 9.5 minutes, and the fistula was placed without bleeding
complications. Within 24 hours, the bleeding time rose again to over 20
minutes. The patient has been maintained on a program of maintenance
hemodialysis. He remains free of overt bleeding.
Discussion
DR. DANIEL DEYKIN (Maurice B. Strauss Professor of Medi-
cine, Boston University and Tufts University Schools of Medi-
cine, and Chief, Medical Service, Boston Veterans Administra-
tion Medical Center, Boston, Mass.): Uremic bleeding reflects
a complex disorder of hemostasis. Although many assays of the
hemostatic mechanisms are abnormal in patients with renal
failure, the single test that most closely correlates with clinical
bleeding is the bleeding time, a global measure of the formation
of the primary hemostatic plug [1—3]. Until recently, the cause
of the uremic defect in primary hemostasis has been obscure.
But two new studies, one from our laboratories [4] and a
subsequent report by Mannucci and associates in Milan, Berga-
mo, and La Jolla [5], have shed some new light on this problem.
These studies demonstrated that administration of agents that
increase the level of the Factor VIII:von Willebrand complex in
uremic patients results in a shortening of prolonged bleeding
times and in a transient reversal of the bleeding tendency.
Before commenting on the clinical and pathophysiologic
implications of these novel observations, I first would like to
review our present understanding of the hemostatic mecha-
nism, placing particular emphasis on primary hemostasis and
the role of the von Willebrand factor in the formation of a stable
platelet plug [6]. Hemostasis is initiated by vascular injury and
culminates in the formation of a firm mechanical barrier that
prevents the continued escape of blood from a damaged blood
vessel. Three groups of reactions, each alone insufficient to
stop bleeding, occur in concert to effect hemostasis (Fig. 1).
The first series of reactions leads to the creation at the site of
vascular injury of a primary hemostatic plug composed of
platelets. Second, activation of the coagulation mechanism,
which generates thrombin and leads to fibrin deposition, stabi-
lizes and strengthens the initially friable platelet plug. Third, a
series of limiting reactions prevents unchecked evolution of
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Fig. 1. The normal hemostatic sequence. TPL refers to thromboplastin.
(From Ref. 6.)
thrombin and fibrin deposition and confines the hemostatic
process to the site of vascular injury. Finally, the hemostatic
mechanism is fully effective only in contracted blood vessels,
because the full axial force of unhampered blood flow would
dislodge the developing plug.
Primary hemostasis is initiated when vascular injury disrupts
the endothelium, exposing subendothelial connective tissue to
the flowing blood (Fig. 2). Platelets are attracted by and bind to
subendothelial collagen. As platelets adhere, they undergo a
series of alterations collectively termed "the release reaction."
A marginal band of tubules within the platelet contracts, forcing
the contents of storage granules into an open canalicular system
that extends to the surface of the platelet. Among the compo-
nents released from the platelet are calcium, serotonin, coagula-
tion factors (factor V, fibrinogen), the von Willebrand protein,
proteolytic enzymes, cationic proteins, a powerful smooth
muscle cell mitogen, and the nucleotide adenosine diphosphate.
The last of these, ADP, has a marked effect on platelets: it
causes them to swell and makes their membranes "sticky," so
that additional platelets adhere to the growing plug. When these
additional platelets adhere, they also undergo the release reac-
tion and liberate more ADP. Therefore, ADP serves both as a
chemical mediator and as an amplifier of the initial stimulus
triggered by vascular injury.
A second mediator also participates in the buildup of the
platelet plug. As platelets adhere to collagen, platelet mem-
brane phospholipases are activated, cleaving arachidonic acid,
a long-chain unsaturated fatty acid, from platelet phospholipids.
A second enzyme, cyclooxygenase, transforms the arachidonic
acid into cyclic endoperoxides, and a third enzyme, thrombox-
ane synthetase, further transforms the endoperoxides into a
labile substance called thromboxane A2 (TXA2) [71. Like ADP,
TXA2 is a potent platelet aggregator. In addition, it is a
powerful vasoconstrictor that promotes the vessel contraction
necessary for normal hemostasis. Both ADP and TXA2 are
necessary for full amplification of the release reaction. Aspirin
specifically inhibits cyclooxygenase and blocks the formation of
cyclic endoperoxides and, therefore, of TXA2; aspirin-treated
platelets do not liberate ADP normally in response to ADP or
collagen.
In addition to mediators that enhance platelet aggregation,
another platelet component, the von Willebrand protein, is
required to fully bind platelet aggregates to subendothelial
collagen. This factor permits binding sufficient to allow the
bound aggregate to resist the disruptive shear stress of flowing
blood. In the absence of the von Willebrand factor, single
platelets adhere to collagen, and the release reaction proceeds
normally. The adherence of the platelet aggregate as a whole
(the "plug"), however, is defective.
The von Willebrand protein is synthesized in two sites:
endothelial cells and megakaryocytes. The protein, composed
of protomeric subunits with molecular weights of approximate-
ly 220,000 daltons, is arranged in a complex array of multimers.
In the circulating platelet and in the endothelial cell, these
multimers range in molecular weight from approximately 106 to
greater than l0. In plasma, the molecular weight range is more
restricted, from 106 to less than l0. Endothelial cells release
von Willebrand factor multimers directly into plasma and
presumably are the primary source of plasma von Willebrand
factor [8, 91. Platelets also release von Willebrand factor during
the release reaction, but the platelet-derived multimers released
are concentrated primarily in the interstices of the platelet plug
[101. The absence of the largest multimeric forms in plasma
suggests that the large forms are processed selectively. Data
obtained from patients who have bleeding tendencies in the
absence of the higher-molecular-weight forms [11] and from
individuals who have excessive platelet aggregates in associa-
tion with the higher-molecular-weight forms in plasma [12]
suggest that the higher-molecular-weight forms have a more
important role in hemostasis than do the lower-molecular-
weight forms.
In addition to their role in promoting platelet adherence to
subendothelial tissue, the plasma von Willebrand multimers
have a second function. They serve as transport proteins for
clotting Factor VIII, the antihemophilic factor. In the absence
of von Willebrand multimers in the plasma, as in severe type-I
von Willebrand's disease [11, 13], clotting Factor VIII is not
released into the plasma from its site of synthesis, presumably
the liver. The converse is not true; in the absence of the
antihemophilic factor, as in severe classic hemophilia, plasma
von Willebrand factor levels are normal.
So far we have reviewed the elements that foster the forma-
tion of the primary hemostatic plug. Clearly, counterbalancing
factors must limit the process of platelet accretion, to confine
the plug to sites of vascular injury. One of the most important of
these limiting factors is prostaglandin 12 (PGI2), or prostacyclin,
which is elaborated by endothelial cells. As in platelets, endo-
thelial cell phospholipases are activated by vascular injury.
They release arachidonic acid from phospholipids. Again, as in
platelets, endothelial cyclooxygenase converts the arachidonic
acid into cyclic endoperoxides. In the endothelial cell, these are
transformed by specific enzymes to PGI2, a powerful vasodila-
tor and inhibitor of platelet aggregation.
Many tests are available for assessing primary hemostasis
(Table 1). The bleeding time, a global measure of primary
hemostasis, is influenced by vascular contractility, platelet
count, platelet function, and the presence of effective levels of
the von Willebrand factor. Until recently, the bleeding time was
a highly variable and imprecise test, but the introduction of
automated devices that ensure reproducibility of the depth and
length of the dermal incision have made the bleeding time a
useful screening test for primary hemostasis [14—16]. Platelet
Vessel wall injury
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Test Assays
Bleeding time Global screening test of pri-
mary hemostasis
Platelet aggregation
Collagen Adherence, release
ADP Release
Arachidonic acid Cyclooxygenase
Glass-bead retention Adherence, release
Platelet factor 3; prothrombin Binding of activated coagula-
consumption tion factors to platelet
surface
Factor VIII:C Factor VIII clotting activity
Factor VIII:CAg Factor VIII coagulant antigen
VWF:Cof von Willebrand factor function
(ristocetin cofactor activity)
VWF:Ag von Willebrand factor antigen
level and structure of
multimers
aggregometry measures the ability of platelets to respond to
exogenous stimuli. Collagen-induced aggregation tests deter-
mine the platelets' ability to adhere to collagen and to undergo
the release reaction. Aggregation induced by ADP measures the
release reaction alone, and arachidonic acid aggregation reflects
the function of platelet cyclooxygenase and thromboxane syn-
thetase. The retention of platelets on glass-bead columns mea-
sures the interaction of platelet adherence, platelet aggregation,
and red blood cell ADP release. Platelet factor 3 (PF-3) and
prothrombin consumption tests are indices of the binding of
clotting factors to platelet membranes. Because the platelets
first must undergo a shape change and the release reaction
before they bind activated clotting factors, these tests provide
indirect estimates of the release reaction.
Assays of the Factor VIII complex are designed to test
separately the function and amount of the individual compo-
Fig. 2. Primary hemostasis. Platelets adhere to
subendothelial collagen (I). They release ADP
and liberate thromboxanes (TBX) (2). They
aggregate (3) in response to ADP and
thromboxane, causing further aggregation. As
they aggregate, platelets change shape,
making phospholipids (PF3) available on their
membrane. A component of Factor VIII (the
von Willebrand factor, VWF) is required for
adherence of platelet masses to connective
tissue. (From Ref. 6.)
nents of the complex. The clotting activity of the antihemophilic
factor, Factor VIII:C, is measured by traditional assays based
on the partial thromboplastin time. The protein content and
structure of the factor are measured by immunologic methods
that reflect antigens specific to the clotting factor component of
the complex (Factor VIII:C Ag) [17, 181. The function of the
von Willebrand factor component of the complex is measured
indirectly by the ristocetin cofactor assay. Ristocetin, a posi-
tively charged antibiotic, promotes the binding of von Wille-
brand multimers to platelets and induces non-energy-dependent
platelet agglutination. In the presence of optimal amounts of
ristocetin, the rate of platelet agglutination can be used as a
measure of von Willebrand factor function [19]. The protein
content and structure of the von Willebrand factor can be
measured by immunologic techniques that reflect either the
total antigen content or its distribution on multimers separated
by charge or molecular weight.
As each test of primary hemostasis was developed, abnormal
values in uremic patients were soon reported. Defective PF-3
activity was first described by Lewis, Zucker, and Ferguson
[201. In a subsequent study, Rabner and Hroder confirmed the
frequency of PF-3 abnormalities and showed that PF-3 activity
improved following dialysis [21]. When platelet aggregation
tests became available, defects in these assays were soon
detected in uremic patients [22]. These defects also were shown
to reverse following dialysis [23]. More recently, Remuzzi and
associates reported that veins taken from patients with renal
failure exhibit strikingly greater PG!2 production than do those
from controls [24]. Interestingly enough, maintenance dialysis
did not lessen the increased venous PG!2 production. Remuzzi
also reported that plasma from uremic patients suppressed
TXA2 production from platelets [24]. As with vascular PG!2
production, dialysis did not reverse the diminished TXA2
production exhibited by uremic platelets.
Abnormalities of the Factor Vill-von Willebrand complex
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Table 1. Tests of primary heniostasis
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Author Test
VIII:Ca VWF:Ag" VWF:RCof'
(%) (%) (%) Ag/Cofd
Kazatchkine [27] 180 153 49 3.3
Warrell [28] — 315 402 0.8
Herrmann [29] 267 219 180 1.2
Remuzzi [30] 104 168 164 1.0
Janson [4] 149 298 127 2.4
also have been found in ureinic patients. Nilsson and coworkers
noted that elevated levels of Factor VIII clotting activity
accompanied chronic renal failure [25, 26]. Similar data were
reported by Kazatchkine and colleagues, who found elevated
von Willebrand factor antigen levels [27]. Finding ristocetin
cofactor activity not proportionately elevated, but in fact lower
than normal, Kazatchkine suggested that chronic renal failure
was accompanied by a functional abnormality of the von
Willebrand factor that might partly explain the prolonged
bleeding time in chronic renal failure.
Four additional studies examined the relationship between
von Willebrand factor levels and function in chronic uremia [4,
28—30] (Table 2). None disclosed decreased levels of von
Willebrand factor functional activity; on the contrary, all four
reported elevated levels. Three demonstrated no major discrep-
ancy between von Willebrand factor antigen level and function-
al activity. In our study, however, the von Willebrand factor
activity was consistently lower than the antigen level.
The structure of the plasma von Willebrand multimers in
uremic plasma has been examined carefully in three studies [4,
5, 281. No abnormality was found in any of these investigations.
Taken together, the data do not support the concept that a
specific structural or functional abnormality of circulating plas-
ma von Willebrand multimers exists in patients with chronic
renal failure.
I would like to recount a clinical experience that led to a
reawakening of interest on our part in the potential role of the
Factor Vill-von Willebrand complex in the pathogenesis of the
hemostatic defect in renal failure. Three years ago, we were
asked to consult on a 62-year-old man with chronic renal failure
who had developed severe rectal bleeding associated with an
inflammatory cecal mass. The patient was being maintained on
hemodialysis. Although he had a normal platelet count, his
bleeding time exceeded 30 minutes. In the hope that we might
achieve transient improvement in hemostasis, we recommend-
ed platelet transfusions, but the bleeding time did not shorten.
A few months previously, Gerritsen, Akkerman, and Sixma had
reported that the infusion of cryoprecipitate, the material that
remains insoluble when plasma is frozen and then thawed at
4°C, shortened the bleeding time in patients who have a specific
form of inherited platelet dysfunction, storage pool disease [311.
The mechanism by which cryoprecipitate shortens the bleeding
time in storage pooi disease was unknown, although the materi-
al was known to be enriched in both the VIII:C and the larger
von Willebrand components of the Factor VIII complex [32].
We had just confirmed Gerritsen's observation in one of our
patients with storage pool disease. We followed an admittedly
tenous chain of association: because cryoprecipitate shortened
the bleeding time in patients with inherited platelet disorders by
an unknown mechanism, but one presumably related to the
Factor VIII complex, we hoped that cryoprecipitate also might
be effective in a uremic patient with an acquired disorder of
primary hemostasis. Accordingly, we gave the patient 10 bags
of cryoprecipitate and measured his bleeding time over the next
18 hours. Figure 3 illustrates the dramatic response of the
patient's bleeding time. Within one hour the bleeding time
began to shorten. Ten hours after the infusion, the bleeding time
was 4 minutes and the rectal bleeding stopped. By 18 hours
after the infusion, however, the bleeding time again exceeded
30 minutes. We again infused cryoprecipitate. When the bleed-
ing time again had shortened to 6 minutes, a hemicolectomy and
abscess drainage were performed successfully. The surgeon
reported normal hemostasis.
Because of our experience with this patient, we performed
similar studies in an additional 6 patients with uremia and
bleeding times exceeding 15 minutes [4]. After cryoprecipitate
infusion, the bleeding times shortened in all patients; in 5, the
bleeding times returned to normal (Table 3). Five underwent
major surgical or invasive procedures without bleeding abnor-
mally. Our data conclusively demonstrated the usefulness of
cryoprecipitate in the treatment of patients with severe uremic
bleeding. Although the results suggested that the shortening of
the bleeding time reflected the specific effects of the larger von
Willebrand factor multimers present in cryoprecipitate [32], the
mechanism was not established by our study.
Mannucci and associates have extended our findings [5]. A
synthetic analogue of antidiuretic hormone, l-deamino-8-D-
Table 2. Levels of Factor VIII and von Willebrand factor in patients
with chronic renal failure
Cryoprecipitate
10 bags
Cryoprecipitate
10 bags
1 1
a Factor VIII clotting activity.b von Willebrand factor antigen.
von Willebrand factor (ristocetin cofactor activity).
d The ratio of b/c.
Hemicolectomy,
abscess
drained25
20
15
10
a
E
a
E
0)C
'0aa
Time, hours
Fig. 3. Response of bleeding time to cryoprecipitate infusion in a 62-
year-old man with uremia and massive rectal bleeding. The two
infusions were given 20 hours apart. (From Ref. 4.)
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Table 3. Response of bleeding time to cryoprecipitate infusion in 6
uremic mena
Patient Bleeding time" (minutes)
Number of hours
between infusion
and maximal effect
4 hours 24 hours
Before after Maximal after
infusion infusion effect infusion
1 20 6 4 20 4
2c 16 10 4 15 12
3 16 12 8 16" 1
4a 20 12 12 20 4
51 20
15
8
Not done
7
8
16
18
8
6
6 16 9 4 17 6
a Table adapted from Ref. 4.
b Time is rounded to nearest whole minute.
Patient had platelet transfusion prior to cryoprecipitate infusion,
and hemodialysis.
d Value obtained at 36 hours after infusion.
Patient had hemodialysis prior to cryoprecipitate infusion.
Patient received both platelet transfusion and hemodialysis prior to
cryoprecipitate transfusion.
arginine vasopressin (DDAVP), causes the release of von
Willebrand factor multimers from storage sites, presumably
endothelial cells, into the plasma [13, 33, 34]. Mannucci and his
colleagues speculated that if the shortening of the bleeding time
were due to the infusion of the large von Willebrand multimers
in cryoprecipitate, then administration of DDAVP also should
shorten the bleeding time. In a prospective, controlled study,
they gave DDAVP (0.3 pg/kg bw) to 12 uremic patients who had
greatly prolonged bleeding times (Table 4). In 6 patients the
bleeding time shortened to 8 minutes or less. In 5 patients the
bleeding time shortened but remained abnormal; in one patient
the greatly prolonged bleeding time persisted. Following
DDAVP infusion, Factor VIII:C activity, von Willebrand factor
antigen, and von Willebrand factor functional activity rose.
Concomitantly, large multimers appeared in the plasma. The
effect was transient, reaching a peak in most patients within one
to 4 hours. The authors concluded that "even though there is no
direct proof that larger Factor VIII:VWF multimers from
cellular compartments are more effective in promoting platelet
adhesion to the subendothelium and in enhancing hemostasis
the temporal association between their appearance and the
shortening of bleeding time was striking" [5].
Our study with cryoprecipitate and Mannucci's with DDAVP
both pose a dilemma. Neither they nor we demonstrated a
structural abnormality of the von Willebrand multimers in the
plasma of uremic patients, yet both maneuvers that increased
the concentration of all the components of the Factor VIII
complex shortened the bleeding time. Several possibilities are
consonant with these findings. Assays might not be available
yet that are sufficiently sensitive to detect a putative defect in
circulating von Willebrand multimers. Alternatively, plasma
von Willebrand factor multimers might not be the critical
determinants of primary hemostasis. Rather, the release of
large multimers from storage sites and the subsequent process-
ing of the large multimers might be abnormal in uremia. A third
possibility is that increasing the concentration of the Factor
VIII complex might cause nonspecific shortening of the bleed-
Table 4. Response of bleeding time to DDAVP administrationa
Patient
Pre-DDAVP
(minutes)
1 hour after DDAVP
(minutes)
1 10 5
2 >30 12
3 21 6
4 >30 22
5 >30 14
6 15 6
7 >30 8
8 >30 4
9 >30 15
10 11 5
11 >30 12
12 24 14
a Data from Ref. 5.
ing time, but a mechanism for such a nonspecific effect is not
clear. Finally, other components of the Factor VIII complex
might be altered in uremia and might contribute to the bleeding
tendency in chronic renal failure.
My colleague, Dr. Mark Weinstein, has preliminary evidence
indicating that the clotting component of the Factor VIII
complex is indeed altered in uremia. He previously has shown,
using a '25I-labeled antibody directed at the clotting component
of the Factor VIII complex, that the clotting Factor VIII
antigen in normal plasma has an apparent molecular weight of
approximately 240,000 daltons and that thrombin administra-
tion degraded the molecule and replaced it with one having a
molecular weight of 100,000 [35]. Finally, the 100,000 molecular
weight form is replaced with an 80,000 molecular weight form
(Fig. 4). Weinstein has found in virtually all plasma samples
from patients with severe uremia and prolonged bleeding times
that the coagulant portion of Factor VIII is degraded and that a
large proportion of the circulating Factor VIII:C exists in a
lower-molecular-weight form. The coagulant piece circulates
attached to von Willebrand factor multimers; these findings
therefore confirm that the Factor VIII complex is under proteo-
lyic attack in uremic plasma. As with the cryoprecipitate and
DDAVP findings, the present data do not yet incriminate a
specific abnormality as the cause of uremic bleeding, but they
strengthen the argument that abnormalities of the Factor VIII
complex play a major role in the abnormal primary hemostasis
that accompanies uremic bleeding.
Another perplexing feature of the uremic patient's bleeding
tendency is the variable efficacy of dialysis in its prevention or
treatment. There can be little doubt that prior to the institution
of maintenance dialysis programs, uremic bleeding constituted
a major threat to patients with chronic renal failure. With the
widespread use of dialysis in the treatment of patients with
renal failure, the incidence •of significant bleeding declined
substantially.
Although dialysis remains the mainstay of the prevention and
treatment of uremic bleeding, it is not always immediately
effective [2]. In our study, 3 of 7 uremic patients with prolonged
bleeding times had been previously treated with dialysis [4].
Castaldi, Rosenberg, and Stewart found that prolonged bleed-
ing times were improved by dialysis in only 12 of 19 patients
[22]. All 12 of Mannucci's patients in the controlled study of
DDAVP had prolonged bleeding times despite regular hemodi-
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Fig. 4. Thrombin-induced proteolysis of
VI!!C:Ag in plasma. Samples were analyzed
with '251-Fab followed by NaDodSO4/3%
polyacrylamide/O.5% agarose gel
electrophoresis. Gels were stained with
Coomassie blue (A) and autoradiograms were
prepared (B). (From Ref. 35.)
A
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alysis 3 times weekly [5]. Furthermore, Remuzzi and associates
found that dialysis did not immediately clear the plasma factor
responsible for diminished TXA2 and exaggerated PGI2 produc-
tion in uremic patients [241.
It is difficult, therefore, for us to infer a direct causal link
between the retention of uremic toxins such as guanidinosuc-
cinic acid or phenolic acids, known to impair platelet aggrega-
tion in vitro [36—381, and the hemostatic defect in uremia. The
variable relationship between abnormal platelet aggregation
tests and the clinical manifestations of bleeding as well as the
lack of immediate correction of the prolonged bleeding time by
dialysis suggests a more indirect association.
The uremic state engenders a complex and changing derange-
ment of primary hemostasis. Platelet aggregation, binding of
clotting factors to the platelet surface, platelet thromboxane
production, vessel wall prostacyclin, and components of the
circulating Factor VIII complex are all affected. Dialysis, by
reversing the uremic state, returns primary hemostasis toward
normal, but the correction is often incomplete. We cannot
ascribe with certainty a specific cause of uremic bleeding. Of
the various possibilities, abnormal processing of the Factor
VIII complex—its assembly in endothelial cells, release into
plasma, and attachment to platelets and subendothelial tissue—
offers a promising arena for fruitful research. In the meantime,
the availability of cryoprecipitate and DDAVP offers new and
effective treatment for the temporary reversal of uremic bleed-
ing in patients who require urgent invasive procedures.
Questions and answers
DR. NIcoLAos E. MADIAS: Your work [4] and that of
Mannucci and colleagues [5] suggests that, first, there is a wide
variation in how long it takes patients to reach their nadir in
terms of bleeding time after infusion of cryoprecipitate, and,
second, that no correlation exists between the nadir and the
initial bleeding time. Do you have any explanation for these
observations?
DR. DEYKIN: To understand the variable interval between the
infusion of cryoprecipitate and the nadir of the bleeding time, it
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is helpful if one contrasts the bleeding time response to cryopre-
cipitate in patients who have diminished levels of von Wille-
brand factor in their plasma, such as patients with type-I von
Willebrand's disease [13] to those with elevated levels, such as
patients with uremia. In patients with von Willebrand's disease,
the bleeding time shortens promptly following infusion, where-
as in uremia the response is delayed. In patients with the type
lib variant of von Willebrand's disease, in which there are
abnormal forms of circulating multimers [13], the bleeding time
response to cryoprecipitate is also delayed in onset. Weinger
and associates have shown that the delay is caused by the
formation of a complex between the infused normal multimers
and the circulating abnormal multimers [39]. The delay in the
bleeding time response in uremia also might reflect complex
formation between infused normal multimers and circulating
abnormal multimers. However, we have not yet been able to
demonstrate the nature of the abnormal multimers. The pro-
longed bleeding time in uremia probably is due to several
causes, and only one—the putative abnormality in von Wille-
brand factor multimers—would be treated by cryoprecipitate. It
is not surprising, therefore, that there is no direct correlation
between the nadir of the response to cryoprecipitate and the
magnitude of the pretreatment prolongation of the bleeding
time.
DR. KENNETH B. MILLER (Staff Physician, Division of
Hematology-Oncology, NEMC): The bleeding problem of the
majority of uremic patients that we see responds to dialysis, and
only a minority of patients require cryoprecipitate. Do you
believe that this minority has a basic defect that predates renal
failure and that renal failure simply uncovers it?
DR. DEYKIN: I do not think that patients with uremia who
develop bleeding and who fail to respond to dialysis are a subset
of patients with antecedent hemostatic defects. I think that the
hemostatic mechanism in urémic patients is in a precarious
balance created by the generation of uremic toxins and the
ability of residual renal function or dialysis to clear the toxins.
When patients become septic, for example, the balance is
upset, and dialysis is not able to keep up with the deteriorating
hemostasis.
B
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DR. MILLER: Do some patients require less cryoprecipitate
and some more?
DR. DEYKIN: We only have studied our initial regimen using
10 units of cryoprecipitate. If patients do not respond to the
initial 10 units, they have not responded to subsequent cryopre-
cipitate administration. The quality of the cryoprecipitate is
critical. If the preparation lacks the large multimers, it will be
ineffective in shortening the bleeding time.
DR. JOHN T. HARRINGTON: Is there any way to produce a
pure preparation of cryoprecipitate?
DR. DEYKIN: One has to be cautious about "purification" of
cryoprecipitate. Highly "purified" concentrates have a much
greater Factor VIII clotting factor content, but their von
Willebrand factor multimers are degraded [32]. These prepara-
tions are not useful for treating von Willebrand's disease, and I
am sure they also would be ineffective in treating uremic
bleeding.
DR. JEROME P. KASSIRER: Can you expand on the mechanism
by which DDAVP affects the von Willebrand protein or other
parts of the coagulation process?
DR. DEYKIN: Like many other peptides, DDAVP binds to
specific receptors on the endothelial cell. Once bound, DDAVP
has many intracellular effects. It causes the release of von
Willebrand factor multimers stored in endothelial cells, and it
also results in the release of plasminogen activator. How
DDAVP triggers this secretory response by the endothelial cell
is not known.
DR. JERRY MCCAULEY (Staff Nephrologist, Division of
Nephrology, NEMC): Can the effect of DDAVP or cryoprecipi-
tate be sustained chronically? Most of the information currently
available concerns acute responses only. Has anyone given
DDAVP or cryoprecipitate chronically to patients or animals?
DR. DEYKIN: To my knowledge, neither cryoprecipitate nor
DDAVP has been used chronically in the treatment of uremic
bleeding. Of course, cryoprec-ipitate has been used chronically
to treat bleeding episodes in patients with hemophilia or von
Willebrand's disease.
DR. KASSIRER: In a patient with uremic bleeding, should we
carry out an extensive clotting evaluation or perhaps only a
bleeding time, or should we prescribe an initial trial of cryopre-
cipitate or DDAVP without any testing?
DR. DEYKIN: I don't think we have any individual test that
gives more information than the bleeding time. Obviously, you
should have a baseline bleeding time value to assess the acute
response to either cryoprecipitate or DDAVP.
DR. MADIAS: Is the effect described by Mannucci and co-
workers [51 specific to DDAVP, or can it be reproduced by
exogenous infusion of antidiuretic hormone (arginine vasopres-
sin) or by stimulating endogenous antidiuretic hormone release
with, for example, nicotine or an osmotic load?
DR. DEYKIN: Several vasopressin analogues cause release of
von Willebrand multimers, but DDAVP is the most useful
because it produces the fewest side effects.
DR. ANDREW LEVEY (Staff Physician, Division of Nephrolo-
gy, NEMC): It is claimed that peritoneal dialysis is more
efficient than is hemodialysis in correcting uremic bleeding.
Have you had the opportunity to measure von Willebrand's
factor or factor VIII in patients maintained on chronic peritone-
al dialysis?
DR. DEYKIN: We have not comnared peritoneal dialysis with
hemodialysis ourselves. Others have suggested that peritoneal
dialysis might be more effective [40, 41].
DR. JAMES STROM (Acting Chief of Nephrology, St. Eliza-
beth's Hospital, Boston): In a 1980 paper [4], you described 2
patients with abnormal bleeding times related to modest de-
grees of renal insufficiency. As! recall, both patients had serum
creatinine concentrations less than 5.5 mg/dl. Do you think that
patients with relatively low serum creatinine levels might have
disproportionately high levels of another uremic toxin, for
instance, guanidinosuccinic acid, or do these patients just have
a peculiar sensitivity of their Factor VIII complex?
DR. DEYKIN: There is no direct correlation between any
chemical monitor of renal function, such as the serum creati-
nine or BUN level, and uremic bleeding. A better correlation
exists between serum creatinine and abnormal platelet aggrega-
tion, but the clinical relevance of that association is uncertain.
DR. MADIAS: Have you seen any patients with von Wille-
brand's disease and renal failure? If so, how severe is their
hemostatic defect?
DR. DEYKIN: We haven't seen such a combination, but since
both are fairly common, I am sure such patients do exist.
Whether uremia would elevate plasma levels of the Factor VIII
complex in patients with type-I von Willebrand's disease is a
fascinating but as yet unanswered question.
Reprint requests to Dr. D. Deykin, Chief, Medical Service, Boston
Veterans Administration Medical Center, 150 South Huntington Ave-
nue, Boston, Massachusetts 02130, USA
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